SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Space Exploration Technologies Corp., doing business as SpaceX, operates as an aerospace manufacturer, launch service provider, and satellite communications company. It is building the integrated hardware and software infrastructure of the future across space, connectivity, and AI. The firm designs, manufactures, launches, and operates products and services built on cutting-edge technologies, including the rockets and spacecraft. The company was founded by Elon Reeve Musk in 2002 and is headquartered in Starbase, TX.

Space Exploration Technologies Corp. - Ordinary Shares - Class A

SpaceX

SpaceXs stronger-than-expected quarterly results and rapid growth in its AI-compute business, alongside plans for an aggressive expansion, fueled a bullish reaction and a sharp after-hours move. Traders are divided over whether the growth outlook justifies the valuation given heavy capital spending, while some also point to a potential Tesla merger as an additional, uncertain catalyst.

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

Super Micros preliminary quarterly update sharply raised its sales outlook and gross-margin expectations on stronger AI-platform demand, driving a rally and renewed optimism about AI-server growth. Traders largely welcomed the update and debated potential short covering and the stocks valuation, while some remained cautious about whether the gains will hold and whether execution can be sustained.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix shares came under pressure after its earnings report paired a profit beat with a weaker fourth-quarter outlook and a lower advertising-revenue forecast. Traders focused on slowing growth and streaming competition, while some dip buyers argued the selloff was excessive given the companys continued profitability.

Zebec's integrated products - real time payroll apps, on-chain payments infrastructure and networked DePIN - serve companies of all sizes, merchants and individuals and help transcend the boundaries of traditional banking and diminish the role of financial intermediaries.

Zebec Network

ZBCN is drawing attention on a sharp price rebound and a renewed breakout attempt, with traders linking the move to Robinhood Chain and other payroll/payment partnerships. Bullish posts point to expanding adoption, while skeptics say sustained usage, trading volume and token demand still need to confirm the thesis; the Robinhood-related catalyst is also discussed with some uncertainty.

Rocket Lab Corp. engages in the development of rocket launch and control systems for the space and defense industries. It operates through the Launch Services and Space Systems segments. The Launch Services segment provides launch services to customers on a dedicated mission or ride-share basis. The Space Systems segment consists of spacecraft engineering and design services, spacecraft components, spacecraft manufacturing, and on-orbit mission operations. The company was founded by Peter Beck in 2006 and is headquartered in Long Beach, CA.

Rocket Lab Corp.

Rocket Lab USA Inc

Rocket Labs Neutron first flight has been pushed to 2027 after a manufacturing defect in its carbon-composite propellant dome, with replacement work underway. Traders remain divided: some question execution and the lack of a firmer schedule, while others view the selloff as an overreaction and are buying for the long term.

Northrop Grumman Corp. engages in the provision of advanced aircraft systems. It operates through the following segments: Aeronautics Systems, Defense Systems, Mission Systems, and Space Systems. The Aeronautics Systems segment is involved in the design, development, production, integration, sustainment, and modernization of advanced aircraft systems for the U.S. Air Force, the U.S. Navy, other U.S. government agencies, and international customers. The Defense Systems segment includes integrated battle management systems, weapons systems and aircraft, and mission systems sustainment and modernization. The Mission Systems segment offers advanced mission solutions and multifunction systems, primarily for the U.S. defense and intelligence community, and international customers. The Space Systems segment delivers end-to-end mission solutions through the design, development, integration, production and operation of space, missile defense, launch and strategic missile systems for national security, civil government, commercial, and international customers. The company was founded by John K. Northrop, Thomas V. Jones, and Kent Kresa in 1939 and is headquartered in Falls Church, VA.

Northrop Grumman Corp.

Northrop Grummans quarterly results beat expectations, its 2026 outlook was raised, and its backlog reached a record, driving the sharp move higher. Traders are weighing the strong results against a pullback from the session high and whether buyers can sustain the gains.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

Attention is centered on TG Therapeutics MSToronto presentations, especially initial Phase 1 azer-cel data in progressive MS, alongside long-term BRIUMVI and other clinical updates. Traders are positioning ahead of the readouts, with some optimistic about azer-cels potential and others stressing that its clinical impact remains uncertain; ongoing BRIUMVI growth provides a commercial backdrop.

NuScale Power Corp. provides proprietary and innovative advanced small modular reactor (SMR) nuclear technology, with a mission to help power the global energy transition by delivering safe, scalable, and reliable carbon-free energy. Its products include VOYGR SMR Plants and Energy Exploration (E2) Centers. The company was founded by José N. Reyes in 2007 and is headquartered in Corvallis, OR.

NuScale Power Corporation - Ordinary Shares - Class A

NuScale Power Corp

NuScale is under pressure after Barclays downgraded the stock, citing commercial execution risks and delays in securing a definitive TVAENTRA1 agreement for the proposed deployment. Traders debate whether the selloff overstates the risk: bears point to the lack of firm project commitments, while bulls cite AI-driven power demand and NuScales longer-term nuclear opportunity.

International Business Machines Corp. is an information technology company, which engages in the provision of integrated solutions that leverage information technology and knowledge of business processes. It operates through the following segments: Software, Consulting, Infrastructure, Financing, and Other. The Software segment combines hybrid cloud platform and software solutions to help clients become more data-driven, and to automate, secure, and modernize their environments. The Consulting segment focuses on integrating skills on strategy, experience, technology and operations by domain and industry. The Infrastructure segment offers solutions for hybrid cloud and is the foundation of the hybrid cloud stack. Infrastructure is optimized for infusing AI into mission-critical transactions and tightly integrated with IBM Software including Red Hat for accelerated hybrid cloud benefits. The Financing segment refers to the client and commercial financing, facilitating IBM clients’ acquisition of IT systems, software, and services. The company was founded by Charles Ranlett Flint and Thomas J. Watson Sr. on June 16, 1911 and is headquartered in Armonk, NY.

International Business Machines Corp.

IBM is drawing attention ahead of its quarterly report, with traders focused on managements outlook and whether demand is improving after earlier weakness. Some see recent gains and bullish options activity as encouraging, while others worry the stock could fall again if results or guidance disappoint.

The Boeing Co. is an aerospace company, which engages in the manufacture of commercial jetliners and defense, space, and security systems. It operates through the following segments: Commercial Airplanes (BCA), Defense, Space and Security (BDS), and Global Services (BGS). The Commercial Airplanes segment includes the development, production, and market of commercial jet aircraft and provides fleet support services, principally to the commercial airline industry worldwide. The Defense, Space and Security segment refers to the research, development, production and modification of manned and unmanned military aircraft and weapons systems for global strike, including fighter and combat rotorcraft aircraft and missile systems, global mobility, including tanker, rotorcraft and tilt-rotor aircraft, and airborne surveillance and reconnaissance, including command and control, battle management and airborne anti-submarine aircraft. The Global Services segment provides services to commercial and defense customers. The company was founded by William Edward Boeing on July 15, 1916, and is headquartered in Arlington, VA.

Boeing Co.

Boeing Co

FAA certification of Boeings 737 MAX 10 is the dominant catalyst, with bulls viewing it as a step toward deliveries and cash generation while skeptics say approval alone may not move the stock. Traders largely focus on whether Boeing can ramp production and convert its backlog into actual deliveries.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Summit Therapeutics Announces Opening of Global Phase II Study of Ivonescimab-Based Regimens in Advanced Clear Cell Renal Cell Carcinoma

Summit Therapeutics Inc. (NASDAQ: SMMT) today announced the initiation and opening of clinical trial sites of a multiregional Phase II study of ivonescimab, a novel, potential first-in-class investigational PD-1 / VEGF bispecific antibody, in previously untreated advanced clear cell renal cell...

SMMT Inks Deal With AZN-Daiichi to Study Ivonescimab + Datroway Combos

Summit is teaming up with AstraZeneca and Daiichi to test ivonescimab with Datroway across breast and lung cancers, broadening its potential.

AstraZeneca Completes $2 Billion Equity Investment in Summit Therapeutics

Summit Therapeutics Inc. (NASDAQ: SMMT) today announced the successful closing of AstraZenecas (LSE/STO/NYSE: AZN) strategic equity investment in Summit. The equity investment will support continued acceleration of the development of ivonescimab, a novel, potential first-in-class investigational...

Stocktwits Biotech Dealmaker — Novartis, Sanofi And Novo Sign Week’s Biggest Deals

Equity

Biotech companies this week spent on experimental therapies, including autoimmune drugs, next-generation obesity pills and cancer combinations.

AstraZeneca, Daiichi Sankyo Expand Cancer Push Through Summit Partnership

AstraZeneca & Daiichi Sankyo team up with Summit Therapeutics to test Datroway + ivonescimab combo in triple-negative breast cancer.read more...

Summit Teams Up With Daiichi Sankyo, AstraZeneca For Cancer Therapy Trial – CEO Calls It An ‘Important Expansion’

The firms will begin their collaboration with a Phase 3 study of Ivonescimab in combination with Datroway in first-line triple-negative breast cancer


Daiichi Sankyo, AstraZenca, Summit Partner To Evaluate Datroway Plus Ivonescimab

(RTTNews) - Daiichi Sankyo (4568.TS) and AstraZenca (AZN) have entered into a clinical trial collaboration agreement with Summit Therapeutics (SMMT) to evaluate Datroway (datopotamab deruxtecan) in combination with ivonescimab across multiple solid tumors, including lung and brea...

Summit Therapeutics Announces Clinical Trial Collaboration with AstraZeneca and Daiichi Sankyo to Evaluate Ivonescimab in Combination with TROP2-Directed ADC Datroway

Summit Therapeutics Inc. (Nasdaq: SMMT) today announced a clinical trial collaboration agreement with Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/NYSE: AZN) to evaluate ivonescimab, a novel, potential first-in-class investigational PD-1 / VEGF bispecific antibody, in combination with...

Summit Shares Jump on $2B Strategic Investment From AstraZeneca

SMMT shares jump as AstraZeneca commits $2 billion to accelerate ivonescimab development and expand clinical collaboration.

High-Stakes October Puts These Biotechs in the Spotlight

The biotechnology sector is entering a catalyst-heavy stretch, with Iovance Biotherapeutics (NASDAQ:IOVA), NeOnc Technologies Holdings (NASDAQ:NTHI), and Summit Therapeutics (NASDAQ:SMMT) approaching potentially significant commercial, clinical, and regulatory milestones.

Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL.

Summit Therapeutics Inc

Bearish Sentiment

<ul class="summary-bullets"><li>Novartis inked a deal with China’s Abogen on Friday, marking the week’s largest headline number, at up to $7.8 billion.</li><li>Sanofi and Regeneron, partners since 2007 on the eczema drug Dupixent, said on Thursday they will co-develop four new long-acting antibodies aimed at the same kind of inflammation.</li><li>Novo paid $300 million upfront for rights to HRS-1596 outside mainland China, Hong Kong, Macao, and Taiwan, in a deal worth up to $2.6 billion including milestones.&nbsp;</li></ul><p>Drugmakers spent the week buying time in the categories they cannot afford to lose: experimental autoimmune drugs, next-generation obesity pills and cancer combinations.</p><p>Novartis and Novo Nordisk went to China for early RNA and oral metabolic assets. Sanofi paid to extend the inflammation franchise behind Dupixent. AstraZeneca and Merck, meanwhile, invested in cancer mechanisms.</p><h2 class="st-heading-2">Novartis Bets On An RNA Immune Drug</h2><p>Novartis inked a deal with China’s Abogen on Friday, marking the week’s largest headline number, at up to $7.8 billion. Under the deal, Novartis gets exclusive worldwide rights to ABO2203, an RNA drug designed to make the body produce a protein that clears disease-causing immune cells. The target diseases are autoimmune conditions such as lupus and rheumatoid arthritis.</p><p>Abogen also gave Novartis options on other programs from its RNA platform. The deal includes an upfront payment of $575 million; the remaining $7.2 billion depends on development, approval, and sales milestones, and on those options being taken. Royalties would follow if a drug is sold. The deal still needs customary clearances.</p><h2 class="st-heading-2">Sanofi Pays To Extend Dupixent Franchise</h2><p>Sanofi and Regeneron, partners since 2007 on the eczema drug Dupixent, said on Thursday they will co-develop four new long-acting antibodies aimed at the same kind of inflammation. Sanofi’s $1 billion upfront is the largest cash payment of the week, against a $7.8 billion ceiling at Novartis that is mostly milestones.</p><p>The companies will split development costs and profits on the new drugs equally. Dupixent’s existing split does not change. One candidate, REGN20423, is already in early testing for atopic dermatitis. The other three are expected to enter studies in 2027. The pact also settles litigation between the two companies.</p><h2 class="st-heading-2">Novo Licenses A Once-Weekly Obesity Pill</h2><p>Novo Nordisk’s Tuesday agreement with Hengrui was narrower than the Novartis pact.</p><p>HRS-1596 is ready for early human testing as a once-weekly oral treatment that hits two appetite and blood-sugar pathways, GLP-1 and GIP. Novo paid $300 million upfront for rights outside mainland China, Hong Kong, Macao, and Taiwan, in a deal worth up to $2.6 billion including milestones, plus royalties on sales in that territory. Hengrui has Chinese clearance to start early-stage studies in weight management and type 2 diabetes. The license still needs U.S. antitrust clearance and is expected to close in the fourth quarter.</p><h2 class="st-heading-2">AstraZeneca Invests $2B To Test Summit's Cancer Drug</h2><p>AstraZeneca’s $2 billion investment in Summit Therapeutics, announced late Monday, is equity, not a license. The point is access to ivonescimab, a dual-target antibody that blocks PD-1, an immune brake, and VEGF, a signal tumors use to build blood vessels. The companies will test it with AstraZeneca’s experimental cancer drug sonesitatug vedotin in certain gastrointestinal cancers. Each side keeps the rights to its own molecule.</p><h2 class="st-heading-2">Merck Takes A Lab-Stage Cancer Pill</h2><p>Merck’s Monday deal is the earliest of the week. SPR2015, from SciBrunch, is a lab-stage pill aimed at KRAS G12D, a common cancer mutation with few approved drugs aimed at it. Merck takes worldwide rights for $400 million upfront, in a deal worth up to $2.13 billion, and will book that payment as a third-quarter charge of about $0.13 a share. SciBrunch can earn the rest if the drug hits development and commercial goals.</p><h2 class="st-heading-2">How Did Retail Traders React?</h2><p>On Stocktwits, retail sentiment around <a class="mention" data-mention="$NVS" data-symbol-id="NVS" href="https://stocktwits.com/symbol/NVS" target="_blank">NVS</a> and MRK was 'bearish' at the time of writing, while sentiment around AZN, SNY, and NVO was 'neutral.' Retail sentiment around SMMT and REGN, however, was 'bullish' or 'extremely bullish.'&nbsp;</p><p>Read More: <a href="https://stocktwits.com/news-articles/markets/equity/novo-holds-its-2026-outlook-as-fda-review-of-its-blood-disorder-drug-runs-long/cZDjsS6RBKY">Novo Nordisk Holds Its 2026 Outlook As FDA Review Of Its Blood Disorder Drug Runs Long</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

 Assorted pharmaceutical drugs balancing on each other, conceptional idea .

AstraZeneca PLC

Merck & Co Inc

Novartis AG

Regeneron Pharmaceuticals, Inc.

Sanofi-Aventis

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$16.09
Prev Close	$15.57
Open	$15.50
Dividend Yield	0.00%
50-Day Moving Average	$15.74
Beta	1.60
Avg. Volume	7.56M
PE Ratio	-14.38

52-Week High	$29.23
52-Week Low	$12.07
Market Capitalization	$12.45B
EPS (Annual)	-$1.44
Price to Book	20.26
Revenue Per Employee	$0.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

SMMT Fundamentals